Introduction {#sec1}
============

Decompensated liver cirrhosis (DLC) is a stage in the progression of liver cirrhosis. It is associated with functional impairment of liver and portal hypertension. The main causes of liver cirrhosis include hepatitis B virus (HBV) \[[@B1],[@B2]\], alcohol \[[@B3]\], hepatitis C virus (HCV) \[[@B4]\], and autoimmune liver disease. Stem cell therapy has generated great interest due to an increased incidence of chronic DLC and the shortage of organ donors for liver transplantation \[[@B5]\]. Moreover, DLC has a poor prognosis with elevated short-term mortality, even in steroid-treated patients. Thus, early liver transplantation can be an option for selected patients but is unavailable to the majority of patients \[[@B6]\]. Stem cell-based strategies have been tested as an alternative to organ transplantation.

Although anti-fibrotic drugs have been developed, their efficacy on liver disease is limited. The studies on bone marrow cells (BMCs) have facilitated the application of cellular therapeutics. Furthermore, hepatocytes from bone marrow (BM) have been found in mouse and human livers after BMC transplantation, suggesting that BMCs contribute to liver regeneration \[[@B7]\]. Also, the effect of BMCs injected into fibrotic or injured livers has been investigated. However, BMCs must undergo *in vitro* selection and culture for clinical application. Therefore, a clinical trial using mesenchymal stem cells (MSCs) cannot be started until safety during *in vitro* manipulation is ensured \[[@B11]\]. Although early studies suggested the transdifferentiation of BMCs or MSCs into hepatocytes, the underlying mechanism remains poorly understood. The condition of the liver may be aggravated by antiretroviral therapy (ART), especially for patients infected with human immunodeficiency virus (HIV), thereby necessitating a feasible treatment. The present study enrolled 21 patients who were infected with HIV and developed DLC from April 2010 to June 2016. All patients underwent antiretroviral and liver treatment. Of the 14 patients, 12 underwent splenectomy combined with BMC transplantation through the portal vein. The BMC infusion promoted the reestablishment of the liver and immune system.

Materials and methods {#sec2}
=====================

Patient information {#sec2-1}
-------------------

A total of 17 male and 4 female patients, aged 26--56 (average: 40.3) years, were recruited in the present study. All patients were diagnosed with DLC and HIV and underwent treatment at the Shanghai Public Health Clinical Center, China. Of these, 16 patients developed liver cirrhosis due to HBV infection and 5 due to HCV infection. The present study was approved by the Ethics Committee of the Shanghai Public Health Clinical Center, and all subjects provided informed consent before participation in the present study.

Clinical findings {#sec2-2}
-----------------

Decompensated cirrhosis was identified based on the presence of one of the following clinical characteristics: ascites, bleeding varices, encephalopathy, use of spironolactone without alternative indication, or explicit mention of decompensated cirrhosis. The patients were assessed for serum biochemical indexes, including total serum bilirubin (12.9--56.9 µmol/l), white blood cells (WBCs; 2.1--3.35 × 10^9^/l), hemachrome (56.9--125 g/l), thrombocyte (16--10^6^ × 10^9^/l), alanine aminotransferase (26--47 U/l), aspartate aminotransferase (17--65 U/l), CD4+ T lymphocytes (61--303 cells/µl), CD8+ T lymphocytes (174--324 cells/µl), and CD4+/CD8+ (0.27--1.71). Moreover, 17 patients were graded as Child--Pugh--Turcotte class B (a score of 7--9 on a scale of 5--15, with higher values indicating advanced liver disease) and 4 as class C (score ≥10). Among all patients, 16 presented a history of upper gastrointestinal tract hemorrhage.

Therapeutic intervention {#sec2-3}
------------------------

All patients underwent routine therapy, including diuresis, liver protection, yellowing, albumin supplementation, prevention of gastrointestinal bleeding, ART regimen (lamivudin 300 mg/day, tenofovir 300 mg/day, and lopinavir 400 mg/day), and liver treatment (sofosbuvir 300 mg/day, for HCV infection). Furthermore, 12 patients from the cohort consisting of 14 underwent splenectomy and autologous BMC transplantation through the portal vein and were classified as the combination therapy group. Seven patients who refused splenectomy and received only routine therapy were classified as the routine therapy group because this treatment was carried out only at Shanghai Public Health Clinical Center (Shanghai, China); thus, its efficacy needs to be evaluated.

Splenectomy and autologous BMC transplantation {#sec2-4}
----------------------------------------------

General anesthesia was administered to all patients. Nodular cirrhosis and enlarged spleen were observed. The patients exhibited 500--3500 ml of ascites. Venous access ports were inserted through the right omental vein and subcutaneously implanted in the abdomen. The spleen and a piece of liver were resected for pathological examination. One week after the surgery, 20 ml BMC was obtained by a puncture at the anterior superior iliac spine, which was then injected into the vein via venous access ports. Eventually, the venous access ports were filled with 5 ml of sterile heparinized saline to prevent the formation of clots. The same protocol was followed for autologous BMC infusion at 1 month and 3 months after the surgery.

Blood biochemical analysis {#sec2-5}
--------------------------

Before treatment and 1, 3, 12, and 24 months after the treatment, the serum samples obtained from the patients were analyzed using the DA 3500 Discrete Automatic Chemistry Analyzer (Fuji Medical System Co. Ltd, Tokyo, Japan) to evaluate the serum biochemical indexes, including serum prothrombin time, albumin, and total bilirubin. A Sysmex XS-800i Automatic Blood Cell Analyzer (Sysmex Shanghai Ltd, Shanghai, China) was used to evaluate the routine blood tests such as WBC count, hemoglobin, and platelets.

Flow cytometry analysis {#sec2-6}
-----------------------

Five ml blood sample was collected in ethylenediaminetetraacetic acid (EDTA)-coated tubes. Red blood cells were lysed by adding 5 ml of ammonium chloride-potassium lysis buffer (0.16 M NH~4~Cl, 10 mM KHCO~3~, 0.13 mM EDTA; pH 7.2) for 5 min on ice, followed by washing two times with phosphate-buffered saline. Single-cell suspensions (1  ×  10^6^ cells/sample) were incubated with appropriate antibodies for 45  min at 4°C. Then, the cells were washed and detected using a FACS Canto II flow cytometer (BD Biosciences, CA, U.S.A.). Data were analyzed using FlowJo software (Tree Star, OR, U.S.A.). The following antibodies were purchased from BioLegend (CA, U.S.A.): fluorescein isothiocyanate-labeled anti-CD3, PE-labeled anti-CD4, and APC-labeled anti-CD8.

Statistical analysis {#sec2-7}
--------------------

All patients were followed up for more than 2 years. Descriptive data are expressed as mean ± standard deviation (mean±SD), whereas enumeration data are expressed as a rate. The differences between the samples were analyzed using the rank-sum analysis. Survival analysis was used to compare the survival rates between the two groups. *P*-value \<0.05 was considered statistically significant.

Results {#sec3}
=======

Comparison of pre-treatment baseline data between the two groups {#sec3-1}
----------------------------------------------------------------

The baseline data of the two groups are shown in [Table 1](#T1){ref-type="table"}. No statistical differences were detected in the age, weight, body mass index, CD4+, CD8+, prothrombin time, albumin, total bilirubin, WBCs, platelet, hemoglobin, and liver function between two groups (*P*\>0.05).

###### Comparison of baseline parameters before the treatment in both groups (mean ± SD)

  Groups                Age (years)     Weight (kg)     Body mass index (kg/m^2^)   CD4+ (cells/µl)   CD8+ (cells/µl)   Prothrombin time (s)   Albumin (g/l)   Total bilirubin (g/l)   White blood cells (10^9^/l   Platelet (10^9^/l)   Hemoglobin (g/l)   Liver function (score)
  --------------------- --------------- --------------- --------------------------- ----------------- ----------------- ---------------------- --------------- ----------------------- ---------------------------- -------------------- ------------------ ------------------------
  Combination therapy   40.33 ± 10.44   62.35 ± 13.62   25.67 ± 9.64                239.92 ± 137.19   314.83 ± 168.03   18.55 ± 1.41           33.28 ± 3.78    25.92 ± 17.87           2.53 ± 1.17                  72.58 ± 65.12        87.92 ± 24.46      8.00 ± 1.13
  Routine therapy       45.43 ± 7.65    64.87 ± 17.68   27.93 ± 11.67               184.71 ± 104.04   265.57 ± 131.49   18.14 ± 0.86           32.09 ± 2.72    17.33 ± 6.25            2.67 ± 1.50                  89.43 ± 79.52        91.57 ± 25.00      7.29 ± 0.49
  *t*                   1.122           0.362           0.473                       0.918             0.663             0.687                  0.731           1.514                   0.224                        0.502                0.310              1.577
  *P*                   0.278           0.721           0.642                       0.372             0.516             0.501                  0.475           0.151                   0.825                        0.622                0.762              0.133

Efficacy of combination BMC transplantation with splenectomy and follow-up {#sec3-2}
--------------------------------------------------------------------------

In the combination therapy group consisting of 14 patients, 2 showed intraperitoneal hemorrhage on the day of surgery. The surgical wounds in these patients oozed profusely when the operation was repeated. The bleeding wounds were treated with suture ligation and argon laser knife. Both patients died of abdominal bleeding and liver failure 2 days after the surgery. All other patients were followed up, the appetite and physical strength of the patients improved, and ascites decreased or disappeared \[[Figure 1](#F1){ref-type="fig"}A (a,b)\]. After 4 weeks, the serum biochemical indexes improved gradually and returned to normal. After 12 weeks, the Child--Pugh grade reached grade A. The HIV, HBV, and HCV viral loads were not detected. In the routine therapy group consisting of 7 patients, 6 with nonsurgical treatment died in 2 years due to gastrointestinal bleeding and liver failure, and 1 died of liver failure in the third year.

![Computed tomography and survival analysis after 2 years of follow-up\
(**A**) Computed tomography before and after treatment. (**a**) The liver was obviously atrophic with abundant ascites in the abdominal cavity and enlarged spleen. (**b**) The liver size increased significantly and the ascites almost disappeared after 2 years of follow-up. (**B**) Comparison of survival analysis after 2 years of follow-up. Compared with the routine therapy group, \*\**P*\<0.01.](bsr-40-bsr20191316-g1){#F1}

As shown in [Figure 1](#F1){ref-type="fig"}B, the survival rate was 85.7% in the combination therapy group after 2 years of follow-up, which was significantly higher than 14.3% in the conventional therapy group (*P* = 0.003).

Effect of combination BMC transplantation with splenectomy on the liver synthesis and secretion {#sec3-3}
-----------------------------------------------------------------------------------------------

As shown in [Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}A, no significant difference was noted in the liver function scores between the two groups before treatment (*t* = 1.577, *P* = 0.133). However, after treatment, the liver function score in the routine therapy group increased at significantly 1 (*t* = 0.522, *P* = 0.611), 3 (*t* = 1.789, *P* = 0.099), and 12 (*t* = 4.919, *P* = 0.000) months and that in the combination therapy group significantly decreased at 1 (*t* = 4.707, *P* = 0.000), 3 (*t* = 7.216, *P* = 0.000), and 12 (*t* = 7.505, *P* = 0.000) months as compared with that before the treatment. In addition, the liver function score in the combination therapy group was significantly lower than that in the routine therapy group at 1 (*t* = 4.276, *P* = 0.000), 3 (*t* = 9.153, *P* = 0.000), and 12 (*t* = 13.536, *P* = 0.000) months.

![Effect of BMC transplantation on liver synthesis and secretion\
(**A**) The liver function score before and after the treatment in different groups at different time points. (**B**) The prothrombin time before and after the treatment in different groups at different time points. (**C**) The albumin levels before and after the treatment in different groups at different time points. (**D**) The total bilirubin levels before and after the treatment in different groups at different time points. Compared with the routine therapy group, \**P*\<0.05 and \*\**P*\<0.01.](bsr-40-bsr20191316-g2){#F2}

###### Liver function score before and after the treatment in different groups at various time points

  Patient number   Combination therapy   Routine therapy                                         
  ---------------- --------------------- ----------------- --- --- --- --- ---- --- --- --- ---- -------
  1                56                    8                 6   6   5   5   54   8   8   8   9    Death
  2                36                    8                 6   6   5   5   38   8   8   8   9    Death
  3                32                    9                 6   6   6   6   49   7   7   7   8    Death
  4                27                    7                 6   5   5   5   36   7   7   8   9    Death
  5                41                    10                7   6   6   6   54   7   8   9   10   10
  6                48                    8                 6   5   5   5   48   7   7   8   8    Death
  7                35                    8                 6   5   5   5   39   7   7   7   9    Death
  8                39                    7                 6   5   5   5                         
  9                26                    7                 6   5   5   5                         
  10               54                    10                8   6   6   6                         
  11               54                    7                 6   5   6   6                         
  12               36                    7                 6   5   5   5                         

In the liver synthesis function, the prothrombin time (*t* = 0.696, *P* = 0.495) and albumin (*t* = 0.743, *P* = 0.467) level before treatment did not differ significantly between the two groups. After treatment, the prothrombin time decreased significantly, while the albumin level increased significantly at 1 (*t* = 6.279, *P* = 0.000; *t* = 1.328, *P* = 0.196), 3 (*t* = 8.608, *P* = 0.000; *t* = 2.740, *P* = 0.011), and12 (*t* = 11.144, *P* = 0.000; *t* = 4.523, *P* = 0.000) months, respectively as compared with those before the treatment. Moreover, the prothrombin time also decreased significantly and the albumin level increased significantly at 1 (*t* = 6.692, *P* = 0.000; *t* = 2.853, *P* = 0.011), 3 (*t* = 10.379, *P* = 0.000; *t* = 5.185, *P* = 0.000), and 12 (*t* = 15.583, *P* = 0.000; *t* = 8.884, *P* = 0.000) months, respectively that in the routine therapy group ([Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}B,C).

###### Prothrombin time (s) before and after the treatment in different groups at various time points

  Patient number   Combination therapy   Routine therapy                                                                
  ---------------- --------------------- ----------------- ------ ------ ------ ------ ---- ------ ------ ------ ------ -------
  1                56                    17                15.2   14     14.2   13.6   54   17     18.1   17.4   20.2   Death
  2                36                    19.1              14.8   13.6   14     14.1   38   18.4   18.9   19.2   18.4   Death
  3                32                    17.9              16     14.4   13.8   14.2   49   18.1   18.4   18.1   19.6   Death
  4                27                    18.3              14.1   14.6   14.2   14.1   36   17.8   17.9   19.6   19.8   Death
  5                41                    22.1              17.9   16.2   14.4   14.6   54   19.6   19.8   20.1   17.8   18.6
  6                48                    19.1              16     15.2   14.9   14.7   48   17.4   18.9   19.4   21.2   Death
  7                35                    19.1              14.6   14.3   14.1   14.1   39   18.7   18.4   19.6   18.6   Death
  8                39                    17.1              15.8   14.9   14.2   14.3                                    
  9                26                    17.6              14.6   14     14     13.8                                    
  10               54                    19.6              17.2   16.4   14.1   14.1                                    
  11               54                    17.4              15.3   15.1   14.8   14.8                                    
  12               36                    18,3              14.6   14.1   14.2   14.2                                    

###### Albumin levels (g/l) before and after the treatment in different groups at various time points

  Patient number   Combination therapy   Routine therapy                                                                
  ---------------- --------------------- ----------------- ------ ------ ------ ------ ---- ------ ------ ------ ------ -------
  1                56                    30.8              34.1   34.6   38.6   40.1   54   30.2   30.8   30.6   28.8   Death
  2                36                    33.5              35.6   36.8   38.8   38.9   38   32     31.6   30.2   31.6   Death
  3                32                    27.4              38.2   37.9   38.1   38.8   49   34.6   32.8   32.1   29.8   Death
  4                27                    36.3              36.8   38.6   39.6   41.1   36   31.8   32.6   31.2   31.7   Death
  5                41                    31.3              28.6   34.2   38.2   38.1   54   29.6   30.9   29.1   31.2   30.6
  6                48                    36.2              34.8   34.6   34.8   34.1   48   36.8   34.6   34.9   32.8   Death
  7                35                    37                39.4   36.3   39.1   41.2   39   29.6   31.2   29.8   29.6   Death
  8                39                    34.1              38.4   39.2   39.4   40.2                                    
  9                26                    36.4              33.9   37.3   40     41                                      
  10               54                    28.5              30.9   31.6   34.2   34.2                                    
  11               54                    38.8              39.1   39.8   41.2   41.2                                    
  12               36                    29.1              31.5   37.9   39.8   39.8                                    

As shown in [Table 5](#T5){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}D, the total bilirubin levels in the liver secretion function were not significantly different between the two groups before the treatment (*t* = 1.612, *P* = 0.124). However, after the treatment, the levels decreased significantly in the combination therapy group at 1 (*t* = 0.013, *P* = 0.990), 3 (*t* = 0.147, *P* = 0.885), and 12 (*t* = 3.263, *P* = 0.007) months as compared with those before the treatment. The levels of total bilirubin in the combination therapy group were significantly lower as compared with those in the routine therapy group at 12 months (*t* = 3.758, *P* = 0.001).

###### Total bilirubin levels (g/l) before and after the treatment in different groups at various time points

  Patient number   Combination therapy   Routine therapy                                                                
  ---------------- --------------------- ----------------- ------ ------ ------ ------ ---- ------ ------ ------ ------ -------
  1                56                    12.9              13.6   16.4   16.1   15,2   54   12.9   13.1   12.9   26.8   Death
  2                36                    48.2              38.6   31.6   28.4   26.4   38   20.8   22.1   23.3   31.6   Death
  3                32                    56.9              38.9   32.4   26.8   31.2   49   19.2   18.4   19.8   29.4   Death
  4                27                    16.7              18.9   18.1   17.9   16.6   36   13.5   13.8   14.2   21.8   Death
  5                41                    57.5              65.5   42.6   31.5   37.5   54   14.7   13.8   14.6   22.1   30.6
  6                48                    10.5              10.0   9.6    7.8    6.1    48   11.1   11.9   12.6   23.8   Death
  7                35                    21.8              19.2   8.5    17.0   11.2   39   29.1   27.9   27.2   29.4   Death
  8                39                    19.2              16.4   14.2   14.4   10.6                                    
  9                26                    13.5              5.8    6.1    6.1    6.8                                     
  10               54                    14.7              11.4   11.2   10.6   10.8                                    
  11               54                    11.1              10.8   4.9    5.8    5.9                                     
  12               36                    28                7.6    8.2    6.8    6.8                                     

Effect of combination BMC transplantation with splenectomy on differential blood count {#sec3-4}
--------------------------------------------------------------------------------------

As shown in [Tables 6](#T6){ref-type="table"}--[8](#T8){ref-type="table"} and [Figure 3](#F3){ref-type="fig"}A--C, no significant difference was detected in the WBC counts (*t* = 0.233, *P* = 0.819), hemoglobin levels (*t* = 0.321, *P* = 0.752), and platelet counts (*t* = 0.520, *P* = 0.609) between the two groups before the treatment. After 1, 3, and 12 months of treatment, the WBC counts (*t*~1m~ = 5.946, *P*~1m~ = 0.000; *t*~3m~ = 9.093, *P*~3m~ = 0.000; *t*~12m~ = 8.921, *P*~12m~ = 0.000, respectively), hemoglobin levels (*t*~1m~ = 1.684, *P*~1m~ = 0.104; *t*~3m~ = 3.414, *P*~3m~ = 0.002; *t*~12m~ = 4.235, *P*~12m~ = 0.000, respectively), and platelet counts (*t*~1m~ = 7.247, *P*~1m~ = 0.000; *t*~3m~ = 9.155, *P*~3m~ = 0.000; *t*~12m~ = 7.912, *P*~12m~ = 0.000, respectively) were significantly higher in the combination therapy group than those before the treatment Also, the WBC counts (*t*~1m~ = 4.043, *P*~1m~ = 0.001; *t*~3m~ = 6.712, *P*~3m~ = 0.000; *t*~12m~ = 7.570, *P*~12m~ = 0.000, respectively), hemoglobin levels (*t*~1m~ = 1.222, *P*~1m~ = 0.237; *t*~3m~ = 2.412, *P*~3m~ = 0.026; *t*~12m~ = 3.687, *P*~12m~ = 0.002, respectively), and platelet counts (*t*~1m~ = 4.979, *P*~1m~ = 0.000; *t*~3m~ = 6.255, *P*~3m~ = 0.000; *t*~12m~ = 5.460, *P*~12m~ = 0.000, respectively) were increased as compared with those in the routine therapy treatment group.

![Effect of BMC transplantation on differential blood count\
(**A**) The WBC counts before and after the treatment in different groups at different time points. (**B**) The platelet counts before and after the treatment in different groups at different time points. (**C**) The hemoglobin levels before and after the treatment in different groups at different time points. Compared with the routine therapy group, \**P*\<0.05 and \*\**P*\<0.01.](bsr-40-bsr20191316-g3){#F3}

###### White blood cell count (×10^9^/l) before and after the treatment in different groups at various time points

  Number   Combination therapy   Routine therapy                                                         
  -------- --------------------- ----------------- ------ ----- ----- ----- ---- ----- ----- ----- ----- -------
  1        56                    2.1               6.6    5.4   5.1   6.2   54   2.1   1.9   2.0   2.1   Death
  2        36                    1.9               7.6    6.6   6.4   5.4   38   3.4   3.4   3.2   3.2   Death
  3        32                    2.1               3.9    5.4   5.8   5.6   49   5.6   5.4   5.4   4.6   Death
  4        27                    2.0               8.9    7.1   6.9   7.7   36   1.3   1.1   1.3   2.1   Death
  5        41                    2.5               11.4   8.6   7.6   6.9   54   2.8   2.9   2.9   2.6   2.8
  6        48                    2.6               6.8    6.5   6.3   6.8   48   2.2   2.9   3.0   2.8   Death
  7        35                    3.4               5.1    7.4   7.9   6.8   39   1.3   1.9   1.6   1.9   Death
  8        39                    5.6               5.4    6.4   7.2   6.8                                
  9        26                    1.1               8.5    6.6   6.3   5.8                                
  10       54                    2.8               4.0    4.9   5.0   4.9                                
  11       54                    3.0               5.2    5.5   5.1   5.3                                
  12       36                    1.3               5.1    5.7   5.2   5.2                                

###### Platelet count (×10^9^/l) before and after the treatment in different groups at various time points

  Number   Combination therapy   Routine therapy                                                        
  -------- --------------------- ----------------- ----- ----- ----- ----- ---- ----- ----- ----- ----- -------
  1        56                    36                306   286   255   268   54   35    36    38    32    Death
  2        36                    27                296   326   284   246   38   16    17    18    16    Death
  3        32                    101               412   346   246   289   49   133   128   131   98    Death
  4        27                    56                419   427   310   176   36   36    38    34    36    Death
  5        41                    28                177   286   288   263   54   235   232   241   221   218
  6        48                    32                177   196   208   212   48   128   131   142   182   Death
  7        35                    16                153   187   95    142   39   43    41    42    38    Death
  8        39                    133               312   342   286   268                                
  9        26                    36                258   308   286   268                                
  10       54                    235               248   269   248   242                                
  11       54                    128               296   289   292   266                                
  12       36                    43                290   370   298   274                                

###### Hemoglobin levels (g/l) before and after the treatment in different groups at various time points

  Number   Combination therapy   Routine therapy                                                        
  -------- --------------------- ----------------- ----- ----- ----- ----- ---- ----- ----- ----- ----- -------
  1        56                    107               109   114   126   132   54   107   108   104   98    Death
  2        36                    89                103   129   132   112   38   125   119   128   118   Death
  3        32                    63                89    121   131   134   49   60    62    69    86    Death
  4        27                    55                94    118   121   152   36   115   114   118   106   Death
  5        41                    87                109   112   118   143   54   84    78    89    92    89
  6        48                    120               129   119   121   105   48   86    91    84    88    Death
  7        35                    125               130   119   157   152   39   64    59    69    72    Death
  8        39                    60                88    96    112   121                                
  9        26                    115               103   114   116   121                                
  10       54                    84                68    92    96    102                                
  11       54                    86                91    94    98    106                                
  12       36                    64                104   128   124   128                                

Effect of combination BMC transplantation with splenectomy on the serum levels of CD4+ and CD8+ *in vivo* {#sec3-5}
---------------------------------------------------------------------------------------------------------

No significant difference was detected in the levels of CD4+ and CD8+ between the two groups before the treatment. After 1, 2, and 12 months of treatment, the levels of CD4+ (*t*~1m~ = 2.630, *P*~1m~ = 0.014; *t*~3m~ = 4.285, *P*~3m~ = 0.000; *t*~12m~ = 5.061, *P*~12m~ = 0.000, respectively) and CD8+ (*t*~1m~ = 3.356, *P*~1m~ = 0.002; *t*~3m~ = 4.212, *P*~3m~ = 0.000; *t*~12m~ = 4.814, *P*~12m~ = 0.000, respectively) were significantly higher those before the treatment in the combination therapy group. Also, the levels of CD4+ (*t*~1m~ = 2.385, *P*~1m~ = 0.028; *t*~3m~ = 3.335, *P*~3m~ = 0.004; *t*~12m~ = 4.090, *P*~12m~ = 0.001, respectively) and CD8+ (*t*~1m~ = 2.778, *P*~1m~ = 0.012; *t*~3m~ = 3.077, *P*~3m~ = 0.006; *t*~12m~ = 3.590, *P*~12m~ = 0.002, respectively) in the combination therapy group were significantly higher than those in the routine therapy group ([Tables 9](#T9){ref-type="table"} and [10](#T10){ref-type="table"}, [Figure 4](#F4){ref-type="fig"}A,B).

![Effect of BMC transplantation on the serum levels of CD4+ and CD8+ *in vivo*\
(**A**) The levels of CD4+ before and after the treatment in different groups at different time points. (**B**) The levels of CD8+ before and after the treatment in different groups at different time points. Compared with the routine therapy group, \**P*\<0.05 and \*\**P*\<0.01.](bsr-40-bsr20191316-g4){#F4}

###### Levels of CD4+ (cells/µl) before and after the treatment in different groups at various time points

  Patient number   Combination therapy   Routine therapy                                                           
  ---------------- --------------------- ----------------- ----- ------ ------ ------ ---- ----- ----- ----- ----- -------
  1                56                    61                81    269    341    512    54   58    56    61    68    Death
  2                36                    80                120   366    519    541    38   86    94    80    90    Death
  3                32                    130               244   411    612    636    49   210   240   238   238   Death
  4                27                    265               289   999    1112   1300   36   118   128   146   146   Death
  5                41                    141               235   326    476    467    54   349   368   398   366   326
  6                48                    167               481   496    466    492    48   206   198   228   228   Death
  7                35                    303               864   1087   772    802    39   266   265   289   289   Death
  8                39                    491               768   1127   982    964                                 
  9                26                    157               524   642    395    432                                 
  10               54                    387               357   574    546    552                                 
  11               54                    384               709   698    686    664                                 
  12               36                    313               895   1487   1268   1216                                

###### Levels of CD8+ (cells/µl) before and after the treatment in different groups at different time points

  Patient number   Combination therapy   Routine therapy                                                            
  ---------------- --------------------- ----------------- ------ ------ ------ ------ ---- ----- ----- ----- ----- -------
  1                56                    228               318    368    512    825    54   204   218   236   242   Death
  2                36                    529               621    686    648    796    38   508   514   536   512   Death
  3                32                    256               362    418    478    639    49   234   249   268   238   Death
  4                27                    324               649    1886   1892   2501   36   329   386   332   286   Death
  5                41                    312               462    542    968    999    54   308   332   318   326   348
  6                48                    178               962    986    946    874    48   168   189   196   228   Death
  7                35                    174               269    1486   1828   1648   39   108   198   210   226   Death
  8                39                    680               826    2327   1876   1768                                
  9                26                    183               1179   1783   1215   1189                                
  10               54                    476               362    727    646    668                                 
  11               54                    319               570    612    616    646                                 
  12               36                    119               696    993    876    886                                 

Discussion {#sec4}
==========

HBV and HCV infections may lead to DLC, which is a critical condition with high morbidity and mortality and without adequate treatment. However, for HIV-infected patients, the condition of the liver might aid the immune reconstitution with ART that could be otherwise damaged. Therefore, no curative treatment for HIV-infected patients with DLC leads to the death of patients from liver failure or opportunistic infection \[[@B12]\]. Hitherto, liver transplantation is the most effective treatment for DLC, which also has several limitations, including the shortage of organ donors and high medical expenses. Therefore, stem cell therapy is an alternative option for liver transplantation \[[@B12]\]. Recent evidence showed that stem cell therapy attenuated the clinical conditions of patients with cirrhosis, and improved the liver functions. Stem cells possess the ability of symmetrical self-renewal and pluripotency. Somatic stem cells harbored transgerm layer differentiation potential for migration to the damaged areas; these cells later developed into tissue-committed stem cells \[[@B13]\]. Numerous cytokines and growth factors are secreted by BMCs, which promote their migration into injured tissue and facilitate repair.

Several studies demonstrated that a shortened telomere in the liver cells results in the failure of cell replication during the progress of liver cirrhosis. In mammals, the lost liver cells can be replaced by the remaining hepatocytes. However, sustained injury elicits hepatocyte senescence, which in turn, activates liver progenitor cells, known as oval cells. These oval cells have been reported to up-regulate BM-hematopoietic stem cells (BM-HSCs). Both hepatocytes and cholangiocytes can be derived from BM-HSCs. Cell fusion is a critical mechanism during this process. Additionally, BM-HSCs may also promote the proliferation of endogenous hepatocytes to repair liver injury \[[@B16],[@B17]\]. Therefore, stem cell transplantation has been demonstrated to be effective and safe in the treatment of several liver complications, such as post-hepatic cirrhosis, autoimmune liver disease, and alcoholic liver cirrhosis. The function of the liver can be completely restored after stem cell transplantation for patients with alcoholic liver cirrhosis. However, virus-infected patients may need continuous transplantation to replace the damaged stem cells.

Recently, for autologous BMC transplantation, 100--200 ml of autologous bone marrow was needed to isolate MSCs by gradient centrifugation. Then, the isolated MSCs were injected into the liver via a hepatic artery \[[@B18]\] that supplies \<33% of the liver blood within a short circulating time. Moreover, the hepatic portal vein is optimal for stem cell transplantation because of its long circulating time and an extended occupation in the liver. Additionally, high levels of hepatotropic cytokines and nutrients also benefit the maintenance of stem cells. Only a few side effects, such as embolism, are observed owing to the small diameter of BMCs. The present study demonstrated that the survival time in the combination therapy group was significantly longer than that in the routine therapy treatment group. Whether stem cells are effective in treating DLC is controversial. A meta-analysis showed that umbilical cord hepatocytes improve the liver function, relieve clinical symptoms, and improve the quality of life in patients with DLC as compared with the traditional supportive care \[[@B19]\]. Another meta-analysis found that tissue-derived stem cell treatment improves the liver function without complications; however, no difference is detected in the liver function and survival as compared with routine therapy \[[@B20]\]. A randomized controlled study in 2018 found that granulocyte colony-stimulating factor with or without hemopoietic stem-cell infusion did not improve liver dysfunction or fibrosis and might be associated with increased frequency of adverse events as compared with routine treatment \[[@B21]\]. The current study found that splenectomy combined with BMC transplantation through the portal vein not only improves the liver function but also improves the 2-year survival rate. Whether or not splenectomy is valuable for the body's immune reconstruction needs further investigation. Therefore, combination BMC transplantation with splenectomy is an effective technique for the infusion and growth of stem cells in the liver.

BM contains MSCs, HSCs, vascular progenitor cells, many precursor cells, and cytokines. Previous studies demonstrated that pulmonary embolism might occur in patients with multiple fractures due to the infiltration of BM into the venous system \[[@B22],[@B23]\]. However, this embolism might be caused by the massive release of tissue factors and adipocytes from the sites of fracture. The capillary network between the hepatic portal vein and hepatic vein can eliminate components such as adipocytes, avoiding the occurrence of embolism during BMC transplantation. The present *in vivo* study did not detect any fat embolism in the hepatic portal venous system and the lung after the infusion of autologous BMCs at different time points. Moreover, the results demonstrated that patients who underwent autologous BMC transplantation combined with splenectomy exhibited normalized WBCs and platelet counts, elimination of ascites, and restored liver function. All patients were classified as Child--Pugh class A, suggesting that BMC infusion improve liver regeneration.

Three months after splenectomy and autologous BMC infusion, the number of CD4+ T lymphocytes was \>300 cells/µl in the patients with no side effects. The liver functions were restored in 12 with no abnormality in the differential blood count. The CD4+ T lymphocytes of these patients were stabilized at \>500 cells/µl. Splenectomy is known to avoid spleen-induced damage of various blood cells, leading to rapid repair of WBCs, red blood cells, and platelets. BMCs drive the localization, differentiation, and proliferation of liver-specific cells to renew the liver function \[[@B24]\]. However, CD4+ T lymphocytes are commonly developed in the thymus from precursor T lineage cells migrated from the BM. Then, the mature CD4+ T cells are released into peripheral blood \[[@B25]\]. The application of ART in HIV-infected patients helps to rebuild the immune system with an increased number of CD4+ T cells. In elderly patients, the number of CD4+ T cells increases slowly due to the involution of thymus. The present study demonstrated that the number of CD4+ T cells increased rapidly after autologous BMC transplantation in the 12 HIV-infected patients with liver cirrhosis, which was faster in the younger patients as compared with the elderly. The precursor T lineage cells derived from the infused BMC were implicated as a critical tool for treating HIV-infected patients. Therefore, splenectomy and autologous BMC infusion promote cellular immunity in patients with HIV infection and liver cirrhosis.

Conclusions {#sec5}
===========

Splenectomy, combined with autologous BMC infusion through the portal vein, is beneficial to HIV-infected patients with DLC. It promotes the recovery of liver function and cellular immune function but may increase the risk of severe complications after the surgery.
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ART

:   antiretroviral therapy

BMC

:   bone marrow cell

DLC

:   decompensated liver cirrhosis

HBV

:   hepatitis B virus

HCV

:   hepatitis C virus

HIV

:   human immunodeficiency virus

MSC

:   mesenchymal stem cell
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